Atropos Health, a leader in transforming real-world clinical data into personalized real-world evidence (RWE), has launched a new AI-driven Commercial Analytics solution designed for life science companies. The announcement expands the company’s suite of tools that support decision-making across real-world data, research and development, health economics and outcomes research (HEOR), medical affairs, and brand strategy. The new solution leverages Atropos Health’s advanced AI platform, ChatRWD®, to deliver fast, accurate, and transparent insights. Commercial and brand leaders can now generate high-quality, brand-specific analytics in seconds, complete with visual dashboards and the underlying data for full transparency and trust. This enables faster, more informed decisions on key business initiatives. “Commercial Analytics is a natural evolution of our core capabilities in RWE and precision medicine,” said Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. “Building on our clinical-grade data quality and accuracy, we’re now empowering biopharma teams to ask more complex questions and access the right data through our expanding Atropos Evidence™ Network—ensuring every analysis is grounded in reliable, real-world insights.” The solution supports a wide range of use cases, including market sizing and segmentation, prescription trend analysis, healthcare professional (HCP) and account targeting, patient journey mapping, switching behavior, market share tracking, salesforce and omnichannel optimization, and launch tracking and uptake analysis. By integrating ChatRWD® and GENEVA OS®, customers can drastically reduce the time between posing a question and receiving a data-backed answer. The platform also taps into a growing library of over 10 million novel studies and analyses, further accelerating insights and strengthening the company’s AI-driven evidence ecosystem. “Starting with point-of-care and clinical decision support, we’ve now extended the power of real-world data to commercial and brand strategy,” said Neil Sanghavi, President and Head of Product at Atropos Health. “With high-quality, timely data, commercial leaders can better allocate resources and drive impact across markets. Our solution delivers that speed and precision at scale.” This launch follows recent milestones, including the integration of American Society of Clinical Oncology® (ASCO®) guidelines into the platform and the presentation of rare disease AI algorithms at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. Atropos Health continues to advance its mission of closing evidence gaps from research to patient care. The company’s GENEVA OS® serves as the operating system for rapid, data-driven healthcare evidence, helping life science and healthcare organizations improve patient outcomes and accelerate medical innovation. For more information, visit www.atroposhealth.com or connect via LinkedIn or X (Twitter).